On Demand 2022 Thursday Program

You can earn up to 7.25 AMA PRA Category 1 Credit(s)TM.

Price: FREE for meeting attendees who purchased a ticket to the Thursday Program, otherwise $99 members, $125 non-members

The Thursday International Food Allergy Symposium focuses on epidemiology and diagnostics, including risk stratification, fatalities, and improved diagnostic methods. There will be several presentations on prevention of food allergies, which will cover some of the more controversial topics, such as the role the skin barrier plays in the development of food allergy.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Address misinformation regarding food allergy originating from different online sources and guide clinicians on how to assist their patients in identifying reliable information on the web and beyond.
  • Discuss the role of the microbiome in food allergy and address common questions regarding the use of probiotics, prebiotics and symbiotics in food allergy management.
  • Describe the biologics currently being investigated for food allergy therapy, risks and benefits and how they may be used in the near future in the allergy clinic.
  • Discuss the early use of moisturizers in infancy with the goal of preventing food allergy development.
  • Identify benefits and risks of using biologics in combination with food immunotherapy versus food immunotherapy alone.
  • Consider key arguments regarding the use of food allergy prevention guidelines in populations of different risk.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
Course opens: 
12/02/2022
Course expires: 
12/01/2025
Cost:
$125.00
Rating: 
0

tbd

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance

Price

Cost:
$125.00
Please login or create an account to take this course.